Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Receivables (2019 - 2025)

Burning Rock Biotech has reported Receivables over the past 7 years, most recently at $25.6 million for Q4 2025.

  • For Q4 2025, Receivables rose 11.07% year-over-year to $25.6 million; the TTM value through Dec 2025 reached $25.6 million, up 11.07%, while the annual FY2025 figure was $25.6 million, 12.87% up from the prior year.
  • Receivables for Q4 2025 was $25.6 million at Burning Rock Biotech, down from $27.5 million in the prior quarter.
  • Over five years, Receivables peaked at $28.9 million in Q2 2023 and troughed at $15.5 million in Q1 2021.
  • A 5-year average of $23.2 million and a median of $23.2 million in 2022 define the central range for Receivables.
  • Biggest five-year swings in Receivables: surged 49.5% in 2022 and later dropped 16.88% in 2024.
  • Year by year, Receivables stood at $21.1 million in 2021, then grew by 1.33% to $21.3 million in 2022, then decreased by 2.59% to $20.8 million in 2023, then rose by 11.13% to $23.1 million in 2024, then rose by 11.07% to $25.6 million in 2025.
  • Business Quant data shows Receivables for BNR at $25.6 million in Q4 2025, $27.5 million in Q3 2025, and $28.3 million in Q2 2025.